[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615798":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":70,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":26,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"University Of Nigeria Teaching Hospital","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment arm","EXPERIMENTAL","Metformin 500mg extended release tablets taken once daily to a maximum dose of 1500mg daily",[13],"Drug: Metformin",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","PLACEBO_COMPARATOR","Identical-looking placebo",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Metformin","Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Starch-based, identical looking placebo",[15],[32],{"name":33,"affiliation":5,"role":34},"IFEYINWA D NNAKENYI, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Chiamaka C Onu, BSc","CONTACT","+2347031800855","mowri2025@gmail.com",[42,60],{"facility":43,"status":44,"city":45,"state":46,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Pathology Facility","RECRUITING","Enugu","Enugu State","Nigeria","NG",{"type":50,"coordinates":51},"Point",[52,53],7.49883,6.44132,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":58,"phoneExt":26,"email":59},"Emeka F Nnakenyi, MD","+2348139427709","pathologyfacility@gmail.com",{"facility":61,"status":44,"city":45,"state":46,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"University of Nigeria Teaching Hospital",{"type":50,"coordinates":63},[52,53],{"lat":53,"lon":52},[66],{"name":67,"role":38,"phone":68,"phoneExt":26,"email":69},"Obinna D Onodugo, MD","+2348035899750","obiokwesili@gmail.com",{"type":34,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Ifeyinwa Nnakenyi","Consultant Chemical Pathologist and Metabolic Physician",[74],{"name":75,"class":76},"Cures Within Reach","OTHER","100615798","phase-3-effect-of-metformin-use-on-weight-loss-in-obese-non-diabetic-people-mowri-100615798",false,"NCT07297290","Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)","Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People","MOWRI","Inclusion Criteria:\n\n* • Obesity (defined as body mass index ≥ 30kg\u002Fm2),\n\n  * Fasting plasma glucose (\\\u003C7.0mmol\u002FL)\n  * No medical treatment for weight control in the previous 12 months\n  * No participation in a current clinical trial\n\nExclusion Criteria:\n\n* • Obesity (defined as body mass index ≥ 30kg\u002Fm2),\n\n  * Fasting plasma glucose (\\\u003C7.0mmol\u002FL)\n  * No medical treatment for weight control in the previous 12 months\n  * No participation in a current clinical trial","ALL","20 Years","59 Years",{"count":89,"type":90},220,"ESTIMATED","INTERVENTIONAL",[93],"PHASE3","Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.\n\nMetformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.",[96,97,98],"Obesity and Cardiovascular Risk","Insulin Resistance","Obesity (Body Mass Index >30 kg\u002Fm2)",[100,101,102,103],"Obesity","Metformin use","Weight loss","Non-diabetic","2025-12-08",{"date":106,"type":107},"2025-12-22","ACTUAL",{"date":109,"type":107},"2025-07-23",{"date":111,"type":90},"2027-09-30",{"name":5,"class":6},2]